This inventor holds 3 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Exelixis, Inc.. Active years: 2021-2026.
Company Filing History:
Years Active: 2021-2026
Title: Christian Scheffold: Innovator in Cancer Treatment
Introduction
Christian Scheffold is a notable inventor based in Palo Alto, CA (US). He has made significant contributions to the field of cancer treatment, particularly through his innovative approaches to therapy. With a total of 3 patents, Scheffold's work focuses on combining existing treatments to enhance their effectiveness against various types of cancer.
Latest Patents
One of his latest patents involves the combinations of cabozantinib and atezolizumab to treat cancer. This invention specifically addresses the treatment of locally advanced or metastatic solid tumors, with a focus on advanced urothelial cancer and renal cell carcinoma. Another significant patent is a method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate. This method is designed for patients who have previously undergone anti-angiogenic therapy using CABOMETYX, a kinase inhibitor.
Career Highlights
Christian Scheffold is currently associated with Exelixis, Inc., a company known for its focus on developing innovative cancer therapies. His work at Exelixis has positioned him as a key player in the ongoing fight against cancer, contributing to advancements that could potentially improve patient outcomes.
Collaborations
Some of his notable coworkers include Gisela Schwab and Colin Hessel, who collaborate with him in the pursuit of innovative cancer treatments.
Conclusion
Christian Scheffold's contributions to cancer treatment through his patents and work at Exelixis, Inc. highlight his commitment to improving therapeutic options for patients. His innovative approaches continue to pave the way for advancements in oncology.